Learning Objectives:
- Discuss the non-T cell inflamed and T cell inflamed tumor phenotypes and the role of β-catenin in the non-T cell inflamed phenotype.
- Discuss the rationale for targeting the β-catenin pathway involved in regulating immune cell responses to tumor.
- Discuss novel high throughput screening methods to identify small molecules that target the β-catenin pathway to promote anti-tumor immune responses.
and
Learning Objectives:
- Understand the rationale for measuring minimal residual disease (MRD) in multiple myeloma (MM)
- Review the advantages and limitations of the techniques used to measure MRD in MM
- Discuss novel high throughput screening methods to identify small molecules that target the β-catenin pathway to promote anti-tumor immune responses.
Session date:
10/15/2018 - 12:00pm to 1:00pm CDT
Location:
UCMC
5841 South Maryland Avenue
MC2115 HemOnc Conference Room E-215
Chicago, IL
60637
United States
See map: Google Maps
Add to calendar:
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation
Speaker Name:
Brian L. Heiss, MD, MA and Benjamin J. Derman, MD